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Introduction: Early identification of chemoresistance in patients with ovarian cancer is of ut-
most importance in order to provide them with the most appropriate therapy. Recently, we
described the expression of MyD88 in ovarian cancer cells that were resistant to the cyto-
toxic agent paclitaxel. In addition to chemoresistance, in MyD88 positive ovarian cancer
cells, paclitaxel stimulates growth and production of proinflammatory cytokines. The objec-
tive of this study was to determine the correlation of MyD88 expression in primary and re-
current epithelial ovarian cancers with the response to carboplatin and paclitaxel
combination chemotherapy. Methods: Tumors are heterogeneous structures that contain
different cell populations, thus rendering the identification of specific tumor markers difficult.
Using laser capture microdissection, pure cancer cells were isolated from ovarian malignant
tumors that were obtained from 20 patients at the time of surgery. The microdissected cells
were evaluated for the expression of MyD88, FasL, and XIAP by western blot analysis. Re-
sults: Protein expression was observed in samples containing as low as 500 cells. The re-
sults were correlated with the clinical course of those patients. It was evident that MyD88
expression in ovarian cancer cells accurately predicts a poor response to paclitaxel
chemotherapy as shown by a short progression-free interval and overall survival. Conclu-
sion: We describe for the first time a molecular approach to identify paclitaxel chemoresis-
tance. Toxicity from agents without therapeutic benefit can be avoided by identifying those
patients who will not respond to a specific agent. Molecular markers will enable us to design
individualized treatments and improve overall survival.
INTRODUCTION
Ovarian cancer is the fourth leading
cause of cancer-related deaths in women in
the United States and the leading cause of
gynecologic cancer deaths. The standard
first-line chemotherapy for patients with
ovarian cancer is a platinum-taxane combi-
nation regimen. In excess of 80 percent of
patients will respond initially to this treat-
ment. However, less than 10 percent will
remain in remission [1].
Recently, we described a sub-group of
epithelial ovarian cancer (EOC)† cells that
express the protein Myeloid Differentiation
Protein 88 (MyD88). MyD88 is an adaptor
protein that is required for Toll-like recep-
tor (TLR) signaling, a signaling pathway
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TLR, Toll-like receptor; LCM, laser capture microdissection; IHC, immunocytochemistry.involved in inflammatory response to bacte-
rial and viral products [2]. EOC cells that ex-
press MyD88 constitutively secrete
pro-inflammatory cytokines and are resistant
to the taxane paclitaxel, which is a known
TLR-4 ligand. UponTLR-4 ligation with ei-
ther LPS or paclitaxel, these cells secrete
higher levels of pro-inflammatory cytokines
and, more importantly, proliferate in culture
[2]. We hypothesized that MyD88 is a spe-
cific marker for paclitaxel resistance and is
required for paclitaxel-induced cell growth
in EOC cells. The objective of this study
was to develop an optimized method that
can detect MyD88 expression in ovarian
cancer tumors and thus function as a bio-
marker for selection of therapy.
Proteomics has emerged as an impor-
tant tool to study biological processes in
both physiological and pathological circum-
stances. Identification of specific proteins as
biomarkers for a disease or condition may
be used for diagnosis and/or therapy. Cur-
rently, however, no optimized method exists
that can sensitively detect ovarian cancer
biomarkers from tumor tissue prior to initi-
ation of therapy.Alimiting factor in the dis-
covery and analysis of potential marker from
tumor samples are the “contaminating” sig-
nals originating from normal cells, including
immune cells, that are infiltrating the tumor.
In order to overcome this difficulty, several
investigators have developed mechanical
and/or chemical approaches to separate the
cellular components of the tumor. However,
the purity of these preparations has never
reached the desired levels required for diag-
nostic.
The use of laser capture microdissec-
tion (LCM) has been proposed as an alter-
native method to obtain pure cell
populations. This approach has been used
successfully to identify RNAexpression and
DNAin stored samples [3,4]. However, de-
termination of RNA in cells obtained by
LCM is time consuming and requires special
measures to prevent RNA degradation. In
the present study, we describe a novel ap-
proach for the detection of protein expres-
sion in as low as 1,000 pure epithelial
ovarian cancer cells dissected by LCM. Fur-
thermore, we demonstrate that MyD88 ex-
pression in LCM-dissected ovarian cancer
cells can be used as a marker for paclitaxel
resistance.
MATERIALS AND METHODS
Patients and samples preparation
Ovarian cancer tissue samples were col-
lected from advanced stage ovarian cancer
patients at the time of surgery. All patients
signed consent forms and the use of patient
samples was approved under Yale Univer-
sity's Human Investigations Committee
(HIC #10425).
Tissues were prepared in small aliquots
and snap-frozen in liquid N2. All samples
were stored in cryovials at -80ʿC until future
use.
Antibodies and reagents for
immunocytochemistry (IHC)
Albumin from bovine serum/BSA was
purchased from Sigma Aldrich, St. Louis,
Missouri.
The primary antibody was Dako OV-TL
mouse monoclonal cytokeratin-7 from
Dakocytomation, Carpinteria, California.
Primary antibody dilution was 1:150 in 1
percent BSAmixed in wash buffer.The sec-
ondary antibody used was biotinylated anti-
mouse IgG (H+L) made in horse from
Vector Laboratories, Burlingame, Califor-
nia. Dilution was 1:200 in 1 percent
BSA/wash buffer. As detection reagent, we
used Streptavidin-HRP Conjugate from
Zymed, San Francisco, California, in a
1:300 dilution.
Antibodies and reagents for
Western blot analysis
Primary antibodies used for Western
blot analysis were rabbit polyclonal anti-
human and mouse antibody to MyD88 (dilu-
tion 1:1000 in PBS-T/1 percent FFPM) from
eBioscience (San Diego, California), mouse
monoclonal anti-human antibodies to
FasL/CD95L(dilution 1:10,000 in PBS-T/1
percent FFPM) from BD Biosciences (San
Jose, California), mouse monoclonal anti-
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1:10,000 in PBS-T/1 percent FFPM) from
BD Biosciences PharMingen (San Diego,
California). Secondary peroxidase-conju-
gated antibodies, anti-rabbit IgG (H+L)
made in goat and anti-mouse IgG (H+L)
made in horse, were purchased from Vector
Laboratories (Burlingame, California).
Slides preparation
In preparation for Laser capture mi-
crodissection, a 5x5 mm tissue sample was
embedded in OCT at -20oC. Eight-micron
sections were cut with the microtome and
collected on Leica glass-foiled PEN-mem-
brane slides.The slides were fixed in 95 per-
cent ethanol for five minutes and stained
with H&E for 30 seconds at RT, followed by
washing in ddH2O for 30 seconds. Dehydra-
tion is required for successful Laser mi-
crodissection, and this was accomplished by
immersing the slides in 95 percent ethanol
and then in Histosolve, a xylene substitute
(Shandon, Inc., Pittsburgh, Pennsylvania),
15 minutes each. The slides were air dried
at RT for 15 minutes. Following dehydra-
tion, to prevent protein degradation, the
samples were either used immediately for
microdissection or they were stored in air-
tight plastic wrapping at -20oC.
Immunohistochemistry for Laser
microdissection
Eight-micron sections were cut with the
microtome, collected on Leica glass-foiled
PEN-membrane slides and fixed in 95 per-
cent ethanol for five minutes as described
above. The slides were then placed in a
staining dish with 0.1 percent H2O2 in 0.1M
PB for 10 minutes to quench for endogenous
peroxidase activity and then washed in wash
buffer three times. Wash buffer was pre-
pared by adding 0.01 percent Triton X-100
(Sigma Aldrich, St. Louis, Missouri) to
0.1M PB. The area around the tissue sec-
tions was scored with a Pap pen to limit the
amount of antibodies and reagents used.All
steps occurred at room temperature with the
slides placed in a moisture chamber to keep
the tissue from drying out during the proce-
dure.To block for non-specific background,
100-200 ﾵl of 3 percent BSA made in wash
buffer were added to the circumscribed areas
and incubated for 20 minutes in the moisture
chamber. Next, the primary antibody was in-
cubated for two hours followed by washing
with wash buffer (each wash is two to three
minutes times three), the specimens were in-
cubated with Biotin labeled secondary anti-
body for 30 minutes. After this incubation,
the slides were washed once with wash
buffer then twice with 0.1M Tris (pH 7.5).
The tissue was incubated with Streptavidin-
HRP conjugate for 30 minutes and then
washed with 0.1 M Tris three times. The
color was developed with DAB (2.5 mg
DAB in 5 ml 0.1 M Tris). Twenty five ﾵl of
0.03 percent H2O2 were added to the chro-
mogen just before use.At the end of the pro-
cedure, the slides were washed with double
distilled water and counterstained with
Mayer’s hematoxylin (Sigma Aldrich, St.
Louis, Missouri).The specimens were dehy-
drated and then stored as described above.
Laser Microdissection for
Western Blot Analysis
The slides were placed inverted into the
holder of a LeicaAS LMD Laser Microdis-
section System with the side containing the
tissue facing down (non-contact method).
Tumor cells were selected according to their
morphology for H&E stained samples or ac-
cording to their immunoreactivity for CK-7
stained samples. Dissected cells were col-
lected in the cup of 0.5ml Eppendorf tubes
containing 35 ﾵl sample buffer (2.5 percent
SDS, 10 percent glycerol, 5 percent ʲ-mer-
capto-ethanol, 0.15M Tris (pH = 6.8) and
0.01 percent bromophenol blue). After a
short centrifugation, lysis of the cells was
achieved by submitting the samples to five
cycles of freezing (liquid N2) and thawing
(95ﾺC) followed by boiling for five minutes,
centrifuged again for two minutes and then
stored at -80oC until further use.
All procedures were carried out in a
timely manner to minimize the activity of
proteases. For H&E stained tissues, the in-
terval from tissue frozen section cutting to
cell dissection and lysis was under one hour
while immunostained (CK-7 or CD45)
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four hours.
Western blot analysis
Proteins were resolved under reducing
conditions on 12 percent SDS-PAGE gels
and then transferred onto polyvinylidene di-
fluoride paper (NEN Life Sciences, Boston,
Massachusetts) [5]. Membranes were
blocked at room temperature for one hour
with 5 percent FFPM in PBS/0.05 percent
Tween 20 (PBS-T). After three washes for
10 minutes, each with PBS-T, membranes
were incubated overnight at 4oC with the
primary antibody in PBS-T/1 percent
FFPM. After incubation with the primary
antibody, membranes were washed three
times with PBS-T and then incubated at
room temperature with the appropriate sec-
ondary antibody conjugated to peroxidase
(Vector Laboratories) in PBS-T/1 percent
FFPM. After three washes for 10 minutes
each with PBS-T and three washes for 10
minutes each with distilled water, the perox-
idase-conjugated antibody was detected by
enhanced chemoluminiscence (PerkinElmer
Life Sciences, Boston, Massachusetts). The
signal intensity was analyzed using a Kodak
digital imaging analysis system (Kodak
Image Station 4000MM) and Kodak Molec-
ular Imaging Software (Scientific Imaging
Kodak Company).
RESULTS
Protein detection in isolated cells
Our first objective was to determine
whether we could detect protein expression
by Western blot analysis in microdissected
cells obtained from ovarian tumor samples
that were snap-frozen in liquid N2.Thus, we
microdissected increasing number of cells
with a maximum of 8,000 cells and a mini-
mum of 100 cells from 8 ﾵm ovarian cancer
sections and then analyzed them for the ex-
pression of MyD88 and other cancer–related
proteins such as XIAP[6-8] and FasL[9,10]
(Fig. 1).As shown in Figure 2, a strong sig-
nal for MyD88 expression was observed in
samples containing 8,000 and 5,000 mi-
crodissected cells, and no signal was de-
tected for samples containing less than 1,000
cells.
In order to determine whether the sensi-
tivity of the assay remains similar for differ-
ent proteins, we evaluated the expression of
XIAP and FasL using the same number of
cells. Contrary to MyD88, XIAP and FasL
expression is detected in samples containing
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Figure 1. Frozen sections of OC were prepared and stained with H&E. The lines indicate
the areas selected for microdissection, then this group of cancer cells is microdissected
using a low power pulse laser. The figure shows two different samples before (pre-cut), dur-
ing (during-cut), and after (post-cut) microdissection.
Pre-Cut During-Cut Post-Cutas little as 1000 and 100 cells, respectively
(Fig. 2).
We then evaluated whether the sample
thickness affects the signal detected by
Western blot. Although increasing the sec-
tion thickness did increase the amount of
protein, it affected cutting time and rendered
dissection extremely difficult.Therefore, we
standardized the method to eight ﾵm sec-
tions. This allows a quick dissection and
provides enough protein to be detected by
Western blot (data not shown).
MyD88 expression is cell-type specific
Tumors are heterogeneous tissues con-
taining normal supporting cells, immune
cells and cancer cells. Immune cells infil-
trate the stroma and may “contaminate” the
protein profile of the tumor sample (Fig. 3).
Indeed, when we analyzed MyD88 expres-
sion in H&E stained samples without using
appropriate markers for cell type identifica-
tion, we found that MyD88 was expressed
in all samples. The explanation for these re-
sults is that the immune cells present in the
tumor tissue and surrounding the cancer
cells express MyD88 (Fig 3A). In an H&E
stained sample, the selection of specific cells
based on their morphology alone is not suf-
ficient to identify intra-tumoral infiltrated
cells.An advantage of the LCM is that it af-
fords the possibility of selecting a specific
group of cells based on the expression of
cellular markers. Therefore, our next objec-
tive was to determine whether immunohisto-
chemistry staining affects the detection of
proteins in microdissected samples. Thus,
we compared the sensitivity of protein de-
tection of cells obtained from H&E stained
samples with cells obtained from immuno-
stained samples. Tumor tissues were im-
muno-stained with either antibodies for
cytokeratin 7 (epithelial marker) or CD45
(pan-leucocyte marker). Specific staining
for cytokeratin 7 and CD45 was observed in
these frozen sections (Figure 3A and data
not shown). When we compared MyD88
and XIAPexpression in cells obtained from
these two preparations, no difference was
observed in the signal intensity for these
proteins between the two groups, suggesting
that the process of IHC does not affect the
samples’integrity (Fig. 3B). Once we estab-
lished that IHC does not affect protein de-
tection, we evaluated MyD88 expression in
ovarian cancer samples after staining for
CD45 (panleukocyte antigen). As shown in
Figure 4, when we dissected only the cancer
cells (CD45 negative cells) and avoided the
immune cells (CD45 positive cells), MyD88
was differentially expressed in tumors from
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Figure 2. Western blot analysis for mi-
crodissected ovarian cancer cells. Eight
microns thick frozen sections of epithelial
ovarian tumors were prepared and stained
with H&E. Different numbers of pure cancer
cells were microdissected and evaluated for
the expression of FasL, XIAP, and MyD88.
1 = 8,000 cells; 2 = 5,000 cells; 3 = 1000
cells; 4 = 100 cells. As shown, a strong sig-
nal was observed for MyD88 expression in
samples containing 8,000 and 5,000 mi-
crodissected cells, and no signal was de-
tected for samples containing less than 1000
cells. For FasLand XIAP, a signal can be ob-
served with as little as 1000 cells.
Figure 3. The presence of strong immune
infiltrate is recognized in ovarian malig-
nant tumors. The frozen sections were
stained with anti-CD45, a specific marker for
leukocytes. A. Papillary serous ovarian ade-
nocarcinoma section with a necrotic center.
B-D. Immune infiltrate cells (darker stain) can
easily be recognized from the cancer cells
(nuclei).different patients with identical pathological
diagnoses.
Clinical correlation between MyD88
expression and Survival/Progression
Free Interval
We evaluated 20 tumor samples from
patients with epithelial ovarian cancer. The
patient characteristics are summarized in
Figure 4. Eleven out of 20 tumors were
MyD88 positive and nine tumors were
MyD88 negative. Figure 5 shows two rep-
resentative samples after CD45 staining in
preparation for the laser capture microdis-
section and MyD88 expression in pure can-
cer cells.
From the MyD88 positive tumors, 7/11
were obtained at the time of initial surgery
from patients who received neoadjuvant
chemotherapy with carboplatin and pacli-
taxel. These patients had persistent or pro-
gression of disease during neoadjuvant
chemotherapy. Even after neoadjuvant
chemotherapy and optimal tumor debulking,
these patients failed postoperative
chemotherapy. Their progression-free inter-
val was zero, and four patients died of dis-
ease in less than one year. In this group,
mean survival was 16 months.
From the MyD88 negative tumor sam-
ples, 5/7 were obtained at the time of initial
surgery from patients with poorly differenti-
ated serous papillary adenocarcinomas.
Three patients were stage IIIC, one was
stage IIIB, and one was stage IIC. In this
group, all patients were treated with carbo-
platin and paclitaxel and the mean progres-
sion-free interval was 35 months. The mean
overall survival in this group was 45
months, and three patients are alive at the
time of this report.
Four of eleven MyD88 positive tumors
were obtained from patients with recurrent
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Figure 4. Effect of IHC on protein stability.
Frozen sections of ovarian tumors were pre-
pared and stained with H&E alone or with an
anti-cytokeratine 7 (CK-7) antibody for ep-
ithelial cells. Different number of cells was
microdissected and evaluated for MyD88 ex-
pression. 1 = 8,000 cells; 2 = 5,000 cells; 3
= 1000 cells; 4 = 100 cells. The original tis-
sue morphology is preserved and contami-
nation from surrounding unwanted cells is
avoided. The process does not influence the
quantity or quality of proteins contained in
the specimen.
Figure 5. Contamination of samples by CD45+ cells. (A) H&E staining and differentiation
of cells based on nuclei morphology alone is not specific enough in frozen samples for ob-
taining pure cancer cells. The mononuclear immune infiltrate, as evident after CD45 staining,
is substantial. The ability to isolate pure cancer cells is greatly increased with IHC Contam-
ination of the sample with immune cells creates a false positive signal. (B) Identification of
cancer cells is facilitated after CD45 staining. (C) Microdissection of CD45 negative cells
creates a sample pure enough to show differential results between chemosensitve (S) and
chemoresistant (R) ovarian cancer patients. Line: area selected for microdissection.
Cdisease who underwent optimal secondary
cytoreductive surgery.All four patients (two
with recurrent stage IC, one with recurrent
stage IIA, and one with recurrent stage IIC)
received carboplatin and paclitaxel. Their
mean progression-free interval after comple-
tion of chemotherapy was three months.
Four MyD88 negative tumor samples
were obtained from patients with recurrent
disease at the time of the secondary cytore-
duction. Postoperatively, these patients were
treated with paclitaxel and carboplatin com-
bination chemotherapy. One patient with
stage IIIC recurred 33 months after primary
treatment and one patient with stage IVAre-
curred 20 months after primary treatment.
Mean progression-free interval in this group
was 14 months.
A statistical significant correlation be-
tween assay prediction of response and pro-
gression-free interval (PFI) was observed in
all these cases (Fig 7). Furthermore, as
shown by the Kaplan-Meier curve in Figure
8, the patients that had MyD88 negative tu-
mors responded better to treatment and had
a significantly longer survival when com-
pared with the patients that had MyD88 pos-
itive tumors (Fig. 8).
DISCUSSION
This study challenges the current ap-
proach of prescribing chemotherapy by re-
lying solely on the pathological diagnosis.
Instead, we propose that determination of
molecular markers be undertaken and incor-
porated into the diagnostic process prior to
treating patients with neoplastic diseases of
the ovary.We show that the status of MyD88
expression may have a significant impact in
chemo-responsiveness and therefore may be
an indispensable piece of information to ob-
tain prior to commencing treatment.
Although the link between inflamma-
tion, NF-ʺB, and cancer progression has
been well characterized, the specific signal-
ing pathway upstream of NF-ʺB is currently
not well elucidated. As mentioned above,
MyD88 is one of the proteins required in
TLR4-mediated early phase NF-ʺB activa-
tion [11]. Our previous studies [2] showed
that Type I epithelial ovarian cancer (EOC)
cells constitutively secrete IL-6, IL-8,
GROʱ, and MCP-1. In response to LPS
stimulation ofTLR4, these cells proliferated
and showed marked increase in the secretion
of these cytokines via the activation of NF-
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Figure 6. Representative figures for MyD88 positive and negative tumors. Although
the histological diagnosis and the clinical stage of the two tumors were identical, the clinical
course of the disease for each patient was different and correlated with MyD88 expression.
Both received the same treatment, consisting of optimal surgical cytoreduction to no residual
disease and combination chemotherapy with carboplatin and paclitaxel. The first tumor was
MyD88 negative and the clinical course of the patient was characterized by complete re-
sponse to Taxol and carboplatin combination therapy. The second tumor proved to be MyD88
negative and the patient had progression of disease during chemotherapy with Taxol and car-
boplatin. She died of disease 11 months later, despite optimal cytoreductive surgery and
chemotherapy with other agents. Line: selected ovarian cancer cells.
Chemosensitive ChemoresistantʺB. In contrast, type II EOC cells do not
constitutively secrete cytokines, and no
changes in cell proliferation or cytokine pro-
duction were observed following treatment
with LPS. The characteristic pro-inflamma-
tory environment generated by Type I EOC
cells was lost upon the knockdown of
MyD88, suggesting that an active MyD88-
dependentTLR4 signaling is responsible for
the LPS-induced, NF-ʺB-mediated EOC
cell proliferation and cytokine secretion.
As mentioned above, paclitaxel, a first-
linechemotherapeuticagentusedinthetreat-
ment of ovarian cancer [12-14], is a known
TLR4 ligand [2,15,16]. Thus, we also deter-
mined if paclitaxel treatment would induce
the same response in type I EOC cells as was
seen with LPS. Our results showed that sim-
ilar to LPS, paclitaxel also induced NF-ʺB
activation,increasedsecretionofpro-inflam-
matory cytokines, and proliferation of type I
EOC cells. In contrast, no cytokine secretion
was observed in type II EOC cells, and more
importantly, they underwent apoptosis in re-
sponse to paclitaxel. These results suggest
that an activated MyD88-dependent TLR4
signaling pathway to NF-ʺB confers EOC
cells the ability to promote a pro-inflamma-
toryenvironmentandthedevelopmentofpa-
clitaxel resistance. It is noticeable of the
specificity of the signaling pathway to pacli-
taxel,sincetreatmentoftypeIEOCcellswith
carboplatin, a chemotherapeutic drug which
is not a TLR4 ligand, did induce neither pro-
liferation nor cytokine production [17]. The
mechanismthatregulatesMyD88expression
inthesetwotypesofcells,andthecorrelation
of MyD88 expression and clinical response
to paclitaxel in patients with EOC, however,
still remains to be determined.
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Figure 7. Kaplan-Meier
curves illustrate the dura-
tion of progression-free in-
terval and overall survival
for patients with MyD88+
and MyD88- primary tu-
mors. The pathological di-
agnosis was papillary serous
adenocarcinoma of the
ovary for all patients. How-
ever, the clinical course and
the response to combination
chemotherapy with carbo-
platin and paclitaxel were
markedly different and corre-
lated with MyD88 expression
in the analyzed tumors.
A. Mean progression-free
interval was zero for pa-
tients with MyD88+ tumors
(n = 7) and 35 months for
patients with MyD88- tu-
mors (n = 5) treated with
carboplatin and paclitaxel.
This difference was statisti-
cally significant (log rank
statistical test p = 0.009).
B. Overall survival accord-
ing to the MyD88 status of
the analyzed tumors shows
divergent Kaplan-Meier
curves and was statistically
significant (-2 log likelihood
ratio test p = 0.022).Moreover, endogenous ligands ofTLR4
such as HMGB1, heparan sulfate and poly-
saccharide fragments of hyaluronan, which
are released from the damaged tissue and
necrotic cells, may also contribute to cancer
progression and paclitaxel resistance [18-
20].
Tumors contain different cell popula-
tions that are incorporated in a heteroge-
neous structure. These different cell types
can be studied after meticulous isolation.
LCM represents an alternative approach to
obtaining pure cancer cells from fresh-
frozen cancer tissue, thus providing an ac-
curate snapshot of the tumor and its
microenvironment in vivo.After lysis, these
cells can be analyzed and their protein ex-
pression characterized by Western blot,
ELISA, and Luminex assays.
Early identification of chemoresistance
in patients with ovarian cancer has important
treatment implications. It allows tailoring of
therapy to individual patients and prevents
the use of cytotoxic drugs with no therapeu-
tic benefit while avoiding toxicities. Unfor-
tunately, no available method exists to pre-
dict the chemoresponse of cancer cells prior
to initiation of therapy.
The standard treatment for ovarian can-
cer is the combination of carboplatin and pa-
clitaxel. Unfortunately, approximately 15
percent of newly diagnosed patients will not
respond to this combination, and their dis-
ease will progress during or shortly after
completion of chemotherapy. This percent-
age of non-responders increases to 65 to 75
percent for recurrent cancers.
Based on these studies, we hypothe-
sized that MyD88 expression can be used as
a marker for paclitaxel-resistance. However,
we found that a limiting factor in the detec-
tion of MyD88 in whole tumors was the
presence of intra-tumoral immune infiltrate.
Immune cells, mainly macrophages, express
high levels of MyD88 and may give a false
positive result.
Utilizing LCM and immunostaining
protocols that allow clear identification of
the desired cell types can overcome this ob-
stacle. In our experiments, CD45 staining
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Figure 8. Immunohistochemistry for MyD88 on paraffin sections. While the immune in-
filtrate is positive for MyD88 in all specimens, the cytoplasm of the cancer cells shows intense
staining for MyD88 in A and B (Type I, MyD88 positive EOC) and none in C and D (Type II,
MyD88 negative EOC).proved to be highly useful for the identifica-
tion and selection of pure cancer cells from
tumor tissue and classification of tumors as
either MyD88 positive or negative.
We found that proteins expressed in
high-levels, such as FasL or XIAP, can be
detected with as low as 1,000 cells. How-
ever, for proteins with lower expression lev-
els, like MyD88, a minimum of 5,000 cells
was required for detection.
The advent of the LCM, used in con-
junction with protein or gene detection tech-
niques, has enabled us to gain a better
perception of the complex interactions that
occur within and among cells in living tis-
sues. In this study, we have found that fresh-
frozen tissue is a suitable material for this
procedure.We have demonstrated in this re-
port how proteins involved in the apoptotic
cascade and chemoresistance of epithelial
ovarian cancer cells can be accurately de-
tected using a three-step approach. First,
tumor specimens are snap-frozen in liquid
nitrogen and eight ﾵm thick specimens are
stained to facilitate the selection of pure
tumor cells. Second, target cells are identi-
fied based on their immunostaining and col-
lected with the LCM system. The third step
involves lysis of the collected cells followed
byWestern blot or Luminex multiplex assay.
The protocol presented here provides a
fast and easy method for analyzing protein
expression in tissues after LCM. We have
used this method to evaluate the correlation
between MyD88 expression and clinical
outcome, and we have found that all patients
who had MyD88 positive tumors presented
with poor progression-free interval and
overall survival after chemotherapy with
carboplatin and paclitaxel, while the patients
with MyD88 negative tumors had an excel-
lent response to chemotherapy. A prospec-
tive clinical study to validate the specificity
and sensitivity of this test aimed at identify-
ing paclitaxel-resistant patients is under
way. We have recently developed an im-
munohistochemistry protocol for MyD88
that is faster, less labor intensive, and can be
applied to paraffin sections (Fig. 8).
In summary, we describe a sensitive
method to determine MyD88 as a potential
marker for chemoresponse to paclitaxel.We
have identified a specific subclass of cancer
patients who, based on their MyD88 expres-
sion, are paclitaxel resistant.The use of mo-
lecular markers like MyD88 will enable us
to design an individualized of treatment,
thereby eliminating toxicity from agents
without therapeutic benefit or even potential
harm, as evidenced by the stimulating effect
of paclitaxel on MyD88 positive EOC.
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